{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:48:44Z","timestamp":1792813724832,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1093\/annonc\/mdq281","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T03:47:43Z","timestamp":1287460063000},"page":"vii107-vii111","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S7","title":["Benefits and adverse effects of endocrine therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"M.","family":"Colleoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq281_bb0010","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","article-title":"Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005","volume":"16","author":"Goldhirsch","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0025","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/annonc\/mdm268","article-title":"Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer","volume":"18","author":"Colleoni","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.sla.0000133355.48672.22","article-title":"Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer","volume":"240","author":"Schoppmann","year":"2004","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdq281_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","article-title":"The Her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy","volume":"8","author":"Ross","year":"2003","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdq281_bb0040","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.2008.17.0829","article-title":"Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine responsive breast cancer. Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very young women (<35 years) with operable breast cancer: features of disease at presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/oxfordjournals.jncimonographs.a003459","article-title":"Adjuvant therapy for very young women with breast cancer: need for tailored treatments","volume":"30","author":"Goldhirsch","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1093\/annonc\/mdq281_bb0055","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","article-title":"Early Breast Cancer Trialists\u2019 Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0060","first-page":"1055","article-title":"Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma","volume":"131","author":"Ravdin","year":"1970","journal-title":"Surg Gynecol Obstet"},{"key":"10.1093\/annonc\/mdq281_bb0065","first-page":"1687","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0070","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO.1989.7.8.1113","article-title":"Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer","volume":"7","author":"Kafmann","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0075","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0080","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"International Breast Cancer Study Group (IBCSG)","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq281_bb0085","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0090","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2001.19.11.2788","article-title":"Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized trial","volume":"19","author":"Berglund","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0095","first-page":"608","article-title":"Analysis at Eight Years by \u2018Nolvadex\u2019 Adjuvant Trial Organisation","volume":"57","year":"1988","journal-title":"Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer Br J Cancer"},{"key":"10.1093\/annonc\/mdq281_bb0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq281_bb0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(87)90762-8","article-title":"Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh","volume":"330","author":"Breast Cancer Trials Committee, Scottish Cancer Trials Office","year":"1987","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/93.6.456","article-title":"Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years","volume":"93","author":"Stewart","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq281_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/bcr536","article-title":"Has tamoxifen had its day?","volume":"4","author":"Baum","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdq281_bb0120","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J Gen Intern Med"},{"key":"10.1093\/annonc\/mdq281_bb0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.seminoncol.2003.08.028","article-title":"Osteopenia and osteoporosis in women with breast cancer","volume":"30","author":"Ramaswamy","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0130","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq281_bb0135","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq281_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0140-6736(93)92407-K","article-title":"Age as prognostic factor in premenopausal breast carcinoma","volume":"341","author":"de la Rochefordiere","year":"1993","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0150","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(00)02292-3","article-title":"Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?","volume":"355","author":"Aebi","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2007.11.6061","article-title":"Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women","volume":"26","author":"Love","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0160","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq281_bb0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0170","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"The BIG 1-98 Collaborative Group","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq281_bb0175","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq281_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq281_bb0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0190","doi-asserted-by":"crossref","first-page":"s14","DOI":"10.3747\/co.v16i0.457","article-title":"Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer","volume":"16","author":"Sehdev","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1006426132338","article-title":"Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen","volume":"64","author":"Paganini-Hill","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdq281_bb0200","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1200\/JCO.2008.21.3553","article-title":"Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial","volume":"28","author":"Schilder","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdq281_bb0205","article-title":"Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial","volume":"27","author":"Ribi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq281_bb0210","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.breast.2005.08.012","article-title":"Acceptance of adjuvant therapy and quality of life issues","volume":"14","author":"Fallowfield","year":"2005","journal-title":"Breast"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_7\/vii107\/480516\/mdq281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T14:15:04Z","timestamp":1635776104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419396887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":41,"alternative-id":["S0923753419396887"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq281","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}